45 West Watkins Mill Road,
Gaithersburg, Maryland 20878
Amplimmune is focused on developing novel co-stimulatory/co-inhibitory molecules that rebalance the immune system and are intended for treating cancer, autoimmune disease, infectious disease, and transplantation. With its strong product-based focus, Amplimmune has rapidly developed three biologic product candidates: AMP-224 is in Phase 1b trials in cancer; AMP-110 for autoimmune diseases in partnership with Daiichi Sankyo; and AMP-514 for cancer. Working closely with its collaborators, Amplimmune is expanding its technology base in the area of immune co-stimulatory/co-inhibitory molecules and has assembled a large foundation of reagents, models, know-how, and intellectual property to further develop its product pipeline as well as to discover novel biomarkers, ligands, and receptors.
Amplimmunem was acquired by MedImmune on October 07, 2013.
Join Mergr to view all 14 acquisitions of companies in 2013, including 4 acquisitions by private equity firms, and 10 by strategics.
Out of 60 sectors in the Mergr database, ranked 56 in number of deals in 2013. The largest acquisition in 2013 was Administradora de Fondos de Pensiones Provida SA - which was acquired by MetLife for $2.0B.
Join Mergr to view this profile - and discover more acquisitions of companies like Amplimmunem.
No obligation. Cancel anytime.